Respiratory Disorders Treatment Market (Disease: Asthma, Chronic Obstructive Pulmonary Disease [COPD], Lung Cancer, Respiratory Tract Infection, Allergic Rhinitis, Cystic Fibrosis [CF], and Others; Drug Class: Bronchodilators, Corticosteroids, Combination Drugs, Antibiotics, Target Therapy, Immunotherapy, CFTR, and Others; Route of Administration: Oral, Nasal, and Injectable; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2030

Description

Nation-wide Initiatives Fuel Breakthrough Innovations for Coronavirus and Respiratory Disorders Treatment

As governments across the world grapple with the ongoing COVID-19 (coronavirus), the India Health Fund (IHF) is inviting applications from innovators to address respiratory and airborne infections through its nation-wide search, Quest 2020. Such initiatives are encouraging effective solutions addressing respiratory disorders treatment. Thus, governments in other countries such as the U.S., Italy, and Spain can take cues from such nation-wide initiatives that can help to control COVID-19.

Since coronavirus directly affects the respiratory system of patients, governments, and laboratories have accelerated their research to minimize the severity of the virus among the affected and new patients. Ongoing R&D activities hold promising potential for innovations in the respiratory disorders treatment market. Top-tier companies in India are extending their arms to fund government initiatives in respiratory disorders treatment market. These initiatives are prioritizing the identification and diagnosis of coronavirus. There is a growing need for pre-validated solutions that can be extended for the treatment of coronavirus and other respiratory conditions.

Startups Innovate in Handheld Devices Capable of Delivering Information on Medication Concentrations

There is a growing demand for handheld devices capable of detecting biomarkers and molecules that deploy instant feedback on respiratory disorders. Hence, NOWA Innovations-a University of California, Irvine (UCI) startup, has introduced Unaresp™, a novel device that identifies inhaled medication concentrations and trains patients to correctly inhale medications. Such innovations are anticipated to boost the expansion of the respiratory disorders treatment market, where the market is expected to reach ~US$ 108 Bn by 2027.

Get a glimpse of the in-depth analysis through our Report Brochure

Companies in the respiratory disorders treatment market are increasing their R&D capabilities to develop devices that deliver information about the quality of the patient’s exhalation and the probability of an inflamed airway. Thus, useful information on airway and breath quality is predicted to improve patient outcomes in the respiratory disorders treatment market. Companies in the market for respiratory disorders treatment are increasing efforts to fast-track the device’s approval with the FDA for future commercialization.

Lung Microbiome Deploys Individual Treatment Decisions and Disease Status

The concept of lung microbiome is acquiring popularity in the respiratory disorders treatment market. Since some of the microorganisms in lungs are uninvited gatecrashers, lung microbiome helps to provide information about the status of an individual’s disease status.

Lung microbiome is as unique as an individual’s fingerprint, thus resulting in guided individual treatment decisions that help improve patient quality of life. The novel technique also has the potential to guide companies in the respiratory disorders treatment market to develop new medicines. As such, modern laboratory techniques are being deployed to gain information about the quantity and specificity of bacteria present in the sputum samples of individuals.

Several factors such as different organisms moving into the airways as well as environmental factors determine the composition of the lung microbiome among individuals. Thus, the importance of ‘friendly’ gut bacteria is gaining widespread acceptance for respiratory disorders treatment. Healthcare providers in the market of respiratory disorders treatment can increase their efficacy in lung microbiome to identify the symptoms and perhaps decipher the slow progression of respiratory infections.

Demand for Equipment in Low-income Countries to Differentiate Asthma against Self-limiting Viral Infections

Asthma is one of the most common non-communicable disease among children, with a high prevalence worldwide. This is evident since asthma dictates the highest revenue among all diseases in the respiratory disorders treatment market, where the market estimated to progress at a healthy CAGR of ~6% during the forecast period. However, challenges concerning non-availability of equipment and medications for the treatment of asthma in low-resource settings pose as a barrier for market growth. Hence, companies in the respiratory disorders treatment market should increase their production capabilities to meet the demands of healthcare facilities in low-income countries.

Sufficient availability of equipment and necessary medications helps healthcare professionals to differentiate between common respiratory conditions such as pneumonia and asthma versus self-limiting viral infections. Apart from this, there is a growing awareness about non-pharmacological interventions that are underutilized, but can ease symptoms of patients requiring respiratory disorders treatment.

Analysts’ Viewpoint

Given the current public health exigencies amidst the COVID-19 crisis, nation-wide search programs inviting innovators to showcase pre-validated solutions are helping to control the virus. The concept of lung microbiome is acquiring widespread acceptance in the respiratory disorders treatment market to demonstrate how microbiomes are associated with other disorders such as cancer, stroke, and obesity.

Non-pharmacological interventions such as cognitive behavioral techniques are helping to improve the quality of life of chronic obstructive pulmonary disease (COPD) patients. However, there is a need to educate asthma and COPD patients on how to take their medications, which is one of the biggest issues that companies face. Hence, companies should gain expertise in devices that train patients on how to properly inhale their medications.

Respiratory Disorders Treatment Market: Overview

The respiratory disorders treatment market for the historical period 2017–2018 and forecast period 2019–2027, increase in incidence of respiratory disorders, surge in supportive care products to meet the rise in demand for treatment of respiratory disorders, entry of new players, and rise in access to healthcare are projected to drive the global respiratory disorders treatment market

According to the report, the global respiratory disorders treatment market was valued at ~US$ 64 Bn in 2018 and is anticipated to expand at a CAGR of ~6% from 2019 to 2027

Rise in Prevalence of Respiratory Disorders and Surge in Adoption of Combination Therapy: Key Drivers

Rise in focus on smart or digital inhalers for administration of asthma or COPD drugs drives the global respiratory disorders treatment market

Combination therapy includes LAMA-ICS and LABA-ICS. Adoption of combination therapy is increasing, as these are more effective than the separate use of bronchodilator and corticosteroid. Moreover, the number of patients being successfully treated with combination therapy has increased.

Regulatory authorities such as the FDA, the European Commission, and the Ministry of Health, Labor and Welfare (MHLW) have approved the use of combination drugs for the treatment of respiratory disorders such as asthma and COPD

According to the WHO, prevalence of allergic diseases in the developed world has increased significantly in the past 50 years. According to the World Health Organization (White Book on Allergy 2011–2012), allergic rhinitis affects around 30% of the global population.

According to the Global Burden of Disease Study, 251 million COPD cases were reported in 2016 and 3.17 million deaths were caused due to the disease in 2015. Therefore, there is a need of early diagnosis and treatment of the disease.

Focus on Geographic Expansion

Most respiratory disorder-related deaths occur in low- and lower-middle income countries. High prevalence of respiratory diseases, increase in availability of quality health care services, and growth of the pharmaceutical industry in emerging economies across the globe are creating lucrative opportunities in the respiratory disorders treatment market in these countries.

China and Japan are likely to present significant opportunities in the market due to the presence of leading players. In November 2015, F. Hoffmann-La Roche Ltd. opened its new pharmaceutical manufacturing center in Shanghai, China.

Rapid adoption of emerging technologies and surge in innovation are the other important aspects that present opportunities in the respiratory disorders treatment market. Moreover, rapid growth and development of the pharmaceutical industry, rise in availability of branded drugs, and increase of burden of respiratory diseases augment the respiratory disorders treatment market.

Patent Expiry of Branded Products and Availability of Generic Equivalents to Hamper Global Respiratory Disorders Treatment Market

Patents prevent other manufacturers from developing drugs that are being exclusively manufactured by the patent holder. Patent expiry of branded drugs has a significant impact on the pharmaceutical industry. Patent expiry hampers the revenue generated from the sale of branded drugs and can affect the market share of a company.

A few players in the respiratory disorders treatment market face the threat of patient expiry, which increases the availability of generic versions of drugs and create pricing pressure on the manufacturers

For instance, AstraZeneca’s Symbicort Turbuhaler went off patent in Europe in 2019, while patents of GlaxoSmithKline plc’s Qvar, Singulair, and Diskus have expired. This is likely to lead to dramatic losses in sales, thereby affecting positions of the companies in the global respiratory disorders treatment market.

Respiratory Disorders Treatment Market: Competition Landscape

This report profiles major players in the global respiratory disorders treatment market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments

The global respiratory disorders treatment market is less fragmented, with the presence of large number of international as well as regional players

Leading players operating in the global respiratory disorders treatment market are 

  • Mylan N.V
  • AstraZeneca plc
  • Boehringer Ingelheim International GmbH
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Novartis AG
  • Sanofi
  • Sunovion Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries
  • CHIESI Farmaceutici S.p.A.
  • Cipla
  • Vertex Pharmaceuticals Incorporated. 

Key Questions Answered in Respiratory Disorders Treatment Market Report

  • What is the scope of growth of combination drugs in the global respiratory disorders treatment market?
  • What will be the Y-o-Y growth of the global respiratory disorders treatment market between 2019 and 2027?
  • What is the influence of changing trends in target therapies on the global respiratory disorders treatment market?
  • Will North America continue to be the most profitable regional market for respiratory disorders treatment providers?
  • Which factors are anticipated to hamper the growth of the global respiratory disorders treatment market during the forecast period?
  • Which are the leading companies in the global respiratory disorders treatment market?

Respiratory Disorders Treatment Market - Segmentation

Disease

  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Lung Cancer
  • Respiratory Tract Infection
  • Allergic Rhinitis
  • Cystic Fibrosis (CF)
  • Others

Drug Class

  • Bronchodilators
  • Corticosteroids
  • Combination Drugs
  • Antibiotics
  • Target Therapy
  • Immunotherapy
  • CFTR
  • Others

Route of Administration

  • Oral
  • Nasal
  • Injectable

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

TABLE OF CONTENT

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Respiratory Disorders Treatment Market

4. Market Overview

    4.1. Introduction

        4.1.1. Route of Administration Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Respiratory Disorders Treatment Market Analysis and Forecast, 2017–2030

        4.4.1. Market Revenue Projections (US$ Bn)

    4.5. Porter’s Five Force Analysis

5. Key Insights

    5.1. Health Care Industry Overview

    5.2. Health Care Industry Overview

    5.3. Pipeline Analysis (asthma, lung cancer, COPD)

    5.4. Disease Prevalence Rate in Key Countries

    5.5. Disease Management

    5.6. Key Market Events

    5.7. Regulatory Scenario

    5.8. Reimbursement Scenario

    5.9. Technological Advancements

6. Global Respiratory Disorders Treatment Market Analysis and Forecast, by Drug Class

    6.1. Introduction & Definition

        6.1.1. Key Findings / Developments

    6.2. Global Respiratory Disorders Treatment Market Value Forecast, by Drug Class, 2017–2030

        6.2.1. Bronchodilators

        6.2.2. Corticosteroids

        6.2.3. Combination Drugs

        6.2.4. Antibiotics

        6.2.5. Target Therapy

        6.2.6. Immunotherapy

        6.2.7. CFTR

    6.3. Others Global Respiratory Disorders Treatment Market Attractiveness Analysis, by Drug Class

7. Global Respiratory Disorders Treatment Market Analysis and Forecast, by Disease

    7.1. Introduction & Definition

        7.1.1. Key Findings / Developments

    7.2. Global Respiratory Disorders Treatment Market Value Forecast, by Disease, 2017–2030

        7.2.1. Asthma

        7.2.2. Chronic Obstructive Pulmonary Disease (COPD)

        7.2.3. Lung Cancer

        7.2.4. Respiratory Tract Infection

        7.2.5. Allergic Rhinitis

        7.2.6. Cystic Fibrosis (CF)

        7.2.7. Others 

    7.3. Global Respiratory Disorders Treatment Market Attractiveness Analysis, by Disease

8. Global Respiratory Disorders Treatment Market Analysis and Forecast, by Route of Administration 

    8.1. Introduction & Definition

        8.1.1. Key Findings / Developments

    8.2. Global Respiratory Disorders Treatment Market Value Forecast, by Route of Administration, 2017–2030

        8.2.1. Oral

        8.2.2. Nasal

        8.2.3. Injectable 

    8.3. Global Respiratory Disorders Treatment Market Attractiveness Analysis, by Route of Administration 

9. Global Respiratory Disorders Treatment Market Analysis and Forecast, by Distribution Channel 

    9.1. Introduction & Definition

        9.1.1. Key Findings / Developments

    9.2. Global Respiratory Disorders Treatment Market Value Forecast, by Distribution Channel, 2017–2030

        9.2.1. Hospital Pharmacies

        9.2.2. Retail Pharmacies

        9.2.3. Online Pharmacies

    9.3. Global Respiratory Disorders Treatment Market Attractiveness Analysis, by Distribution Channel

10. Global Respiratory Disorders Treatment Market Analysis and Forecast, by Region

    10.1. Key Findings

    10.2. Global Respiratory Disorders Treatment Market Value Forecast, by Region

        10.2.1. North America 

        10.2.2. Europe 

        10.2.3. Asia Pacific 

        10.2.4. Latin America 

        10.2.5. Middle East & Africa 

    10.3. North America Respiratory Disorders Treatment Market Attractiveness Analysis, by Region

11. North America Respiratory Disorders Treatment Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. North America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Drug Class, 2017–2030

        11.2.1. Bronchodilators

        11.2.2. Corticosteroids

        11.2.3. Combination Drugs

        11.2.4. Antibiotics

        11.2.5. Target Therapy

        11.2.6. Immunotherapy

        11.2.7. CFTR

    11.3. North America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Disease, 2017–2030

        11.3.1. Asthma

        11.3.2. Chronic Obstructive Pulmonary Disease (COPD)

        11.3.3. Lung Cancer

        11.3.4. Respiratory Tract Infection

        11.3.5. Allergic Rhinitis

        11.3.6. Cystic Fibrosis (CF)

        11.3.7. Others 

    11.4. North America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017–2030

        11.4.1. Oral

        11.4.2. Nasal

        11.4.3. Injectable 

    11.5. North America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2030

        11.5.1. Hospital Pharmacies

        11.5.2. Retail Pharmacies

        11.5.3. Online Pharmacies

    11.6. North America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Country, 2017–2030

        11.6.1. U.S.

        11.6.2. Canada

    11.7. North America Respiratory Disorders Treatment Market Attractiveness Analysis 

        11.7.1. By Drug Class

        11.7.2. By Disease

        11.7.3. By Route of Administration

        11.7.4. By Distribution Channel

        11.7.5. By Country

12. Europe Respiratory Disorders Treatment Market Analysis and Forecast

    12.1. Europe Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Drug Class, 2017–2030

        12.1.1. Bronchodilators

        12.1.2. Corticosteroids

        12.1.3. Combination Drugs

        12.1.4. Antibiotics

        12.1.5. Target Therapy

        12.1.6. Immunotherapy

        12.1.7. CFTR

    12.2. Europe Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Disease, 2017–2030

        12.2.1. Asthma

        12.2.2. Chronic Obstructive Pulmonary Disease (COPD)

        12.2.3. Lung Cancer

        12.2.4. Respiratory Tract Infection

        12.2.5. Allergic Rhinitis

        12.2.6. Cystic Fibrosis (CF)

        12.2.7. Others 

    12.3. Europe Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017–2030

        12.3.1. Oral

        12.3.2. Nasal

        12.3.3. Injectable 

    12.4. Europe Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2030

        12.4.1. Hospital Pharmacies

        12.4.2. Retail Pharmacies

        12.4.3. Online Pharmacies 

    12.5. Europe Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2030

        12.5.1. Germany

        12.5.2. U.K.

        12.5.3. France

        12.5.4. Spain

        12.5.5. Italy

        12.5.6. Rest of Europe 

    12.6. Europe Respiratory Disorders Treatment Market Attractiveness Analysis 

        12.6.1. By Drug Class

        12.6.2. By Disease

        12.6.3. By Route of Administration

        12.6.4. By Distribution Channel

        12.6.5. By Country/Sub-region

13. Asia Pacific Respiratory Disorders Treatment Market Analysis and Forecast

    13.1. Asia Pacific Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Drug Class, 2017–2030

        13.1.1. Bronchodilators

        13.1.2. Corticosteroids

        13.1.3. Combination Drugs

        13.1.4. Antibiotics

        13.1.5. Target Therapy

        13.1.6. Immunotherapy

        13.1.7. CFTR

    13.2. Asia Pacific Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Disease, 2017–2030

        13.2.1. Asthma

        13.2.2. Chronic Obstructive Pulmonary Disease (COPD)

        13.2.3. Lung Cancer

        13.2.4. Respiratory Tract Infection

        13.2.5. Allergic Rhinitis

        13.2.6. Cystic Fibrosis (CF)

        13.2.7. Others 

    13.3. Asia Pacific Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017–2030

        13.3.1. Oral

        13.3.2. Nasal

        13.3.3. Injectable 

    13.4. Asia Pacific Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2030

        13.4.1. Hospital Pharmacies

        13.4.2. Retail Pharmacies

        13.4.3. Online Pharmacies 

    13.5. Asia Pacific Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2030

        13.5.1. China

        13.5.2. Japan

        13.5.3. India

        13.5.4. Australia & New Zealand

        13.5.5. Rest of Asia Pacific 

    13.6. Asia Pacific Respiratory Disorders Treatment Market Attractiveness Analysis 

        13.6.1. By Drug Class

        13.6.2. By Disease

        13.6.3. By Route of Administration

        13.6.4. By Distribution Channel

        13.6.5. By Country/Sub-region

14. Latin America Respiratory Disorders Treatment Market Analysis and Forecast

    14.1. Latin America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Drug Class, 2017–2030

        14.1.1. Bronchodilators

        14.1.2. Corticosteroids

        14.1.3. Combination Drugs

        14.1.4. Antibiotics

        14.1.5. Target Therapy

        14.1.6. Immunotherapy

        14.1.7. CFTR

    14.2. Latin America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Disease, 2017–2030

        14.2.1. Asthma

        14.2.2. Chronic Obstructive Pulmonary Disease (COPD)

        14.2.3. Lung Cancer

        14.2.4. Respiratory Tract Infection

        14.2.5. Allergic Rhinitis

        14.2.6. Cystic Fibrosis (CF)

        14.2.7. Others 

    14.3. Latin America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017–2030

        14.3.1. Oral

        14.3.2. Nasal

        14.3.3. Injectable 

    14.4. Latin America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2030

        14.4.1. Hospital Pharmacies

        14.4.2. Retail Pharmacies

        14.4.3. Online Pharmacies 

    14.5. Latin America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2030

        14.5.1. Brazil

        14.5.2. Mexico

        14.5.3. Rest of Latin America Latin America 

    14.6. Latin America Respiratory Disorders Treatment Market Attractiveness Analysis 

        14.6.1. By Drug Class

        14.6.2. By Disease

        14.6.3. By Route of Administration

        14.6.4. By Distribution Channel

        14.6.5. By Country/Sub-region

15. Middle East & Africa Respiratory Disorders Treatment Market Analysis and Forecast

    15.1. Middle East & Africa Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Drug Class, 2017–2030

        15.1.1. Bronchodilators

        15.1.2. Corticosteroids

        15.1.3. Combination Drugs

        15.1.4. Antibiotics

        15.1.5. Target Therapy

        15.1.6. Immunotherapy

        15.1.7. CFTR

    15.2. Middle East & Africa Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Disease, 2017–2030

        15.2.1. Asthma

        15.2.2. Chronic Obstructive Pulmonary Disease (COPD)

        15.2.3. Lung Cancer

        15.2.4. Respiratory Tract Infection

        15.2.5. Allergic Rhinitis

        15.2.6. Cystic Fibrosis (CF)

        15.2.7. Others 

    15.3. Middle East & Africa Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017–2030

        15.3.1. Oral

        15.3.2. Nasal

        15.3.3. Injectable 

    15.4. Middle East & Africa Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2030

        15.4.1. Hospital Pharmacies

        15.4.2. Retail Pharmacies

        15.4.3. Online Pharmacies 

    15.5. Middle East & Africa Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2030

        15.5.1. GCC Countries

        15.5.2. South Africa

        15.5.3. Rest of Middle East & Africa 

    15.6. Middle East & Africa Respiratory Disorders Treatment Market Attractiveness Analysis 

        15.6.1. By Drug Class

        15.6.2. By Disease

        15.6.3. By Route of Administration

        15.6.4. By Distribution Channel

        15.6.5. By Country/Sub-region

16. Competition Landscape

    16.1. Market Player - Competition Matrix (by Tier and Size of companies)

    16.2. Market Share / Position Analysis, by Company, 2018

    16.3. Competitive Business Strategies

    16.4. Company Profiles

        16.4.1. GlaxoSmithKline plc

            16.4.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.4.1.2. Growth Strategies

            16.4.1.3. SWOT Analysis

        16.4.2. Merck & Co., Inc.

            16.4.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.4.2.2. Growth Strategies

            16.4.2.3. SWOT Analysis

        16.4.3. AstraZeneca

            16.4.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.4.3.2. Growth Strategies

            16.4.3.3. SWOT Analysis

        16.4.4. Boehringer Ingelheim International GmbH

            16.4.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.4.4.2. Growth Strategies

            16.4.4.3. SWOT Analysis

        16.4.5. Novartis AG

            16.4.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.4.5.2. Growth Strategies

            16.4.5.3. SWOT Analysis

        16.4.6. F. Hoffmann-La Roche Ltd. 

            16.4.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.4.6.2. Growth Strategies

            16.4.6.3. SWOT Analysis 

        16.4.7. Teva Pharmaceutical Industries Ltd.

            16.4.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.4.7.2. Growth Strategies

            16.4.7.3. SWOT Analysis

        16.4.8. Sanofi

            16.4.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.4.8.2. Growth Strategies

            16.4.8.3. SWOT Analysis

        16.4.9. Cipla, Inc.

            16.4.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.4.9.2. Growth Strategies

            16.4.9.3. SWOT Analysis

        16.4.10. Sun Pharmaceutical Industries Ltd. 

            16.4.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.4.10.2. Growth Strategies

            16.4.10.3. SWOT Analysis 

        16.4.11. Mylan N.V.

            16.4.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.4.11.2. Growth Strategies

            16.4.11.3. SWOT Analysis

        16.4.12. Takeda Pharmaceutical Company Limited

            16.4.12.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.4.12.2. Growth Strategies

            16.4.12.3. SWOT Analysis

        16.4.13. CHIESI Farmaceutici S.p.A.

            16.4.13.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.4.13.2. Growth Strategies

            16.4.13.3. SWOT Analysis

        16.4.14. Orion Corporation

            16.4.14.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.4.14.2. Growth Strategies

            16.4.14.3. SWOT Analysis

        16.4.15. Vertex Pharmaceutical

            16.4.15.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.4.15.2. Growth Strategies

            16.4.15.3. SWOT Analysis

Choose License Type

Checkout Inquiry Sample